Dr Pollack has received federal funding from the National Institute of Mental Health (NIMH) and National Institute of Drug Abuse (NIDA) to study the longitudinal course of panic disorder, the application of cognitive-behavioral interventions for the reduction of illicit drug use in drug abusers, the impact of terrorist attacks on the development of PTSD and course of disorder in bipolar patients, changes in brain function as assessed by MR Spectroscopy and neuropsychological testing in patients on methadone maintenance, treatment response and pharmacogenetics in refractory social anxiety disorder, and the and use of d-cycloserine to enhance the treatment efficacy of cognitive-behavioral therapy in social anxiety and panic disorder.

He has published over 300 articles, reviews and chapters, and is co-editor of the books "Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies", “Panic Disorder and Its Treatment,” and “Social Phobia: Research and Practice”. Dr. Pollack is editor-in-chief of the journal CNS Neuroscience and Therapeutics, lectures widely in national and international forum, serves on numerous editorial and advisory boards, including the Board of Directors of the Mood and Anxiety Disorders Institute of the Massachusetts General Hospital, and is Chairman of the Scientific Advisory Board of the Anxiety Disorders Association of America.His areas of clinical and research interest include the acute and long-term course, pathophysiology and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.